{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:07:28Z","timestamp":1791860848821,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.pcad.2006.02.002","type":"journal-article","created":{"date-parts":[[2006,5,20]],"date-time":"2006-05-20T11:22:17Z","timestamp":1148124137000},"page":"387-396","source":"Crossref","is-referenced-by-count":46,"title":["Use of Aldosterone Antagonists in Resistant Hypertension"],"prefix":"10.1016","volume":"48","author":[{"given":"David A.","family":"Calhoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2006.02.002_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.290.2.199","article-title":"Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000","volume":"290","author":"Hajjar","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2006.02.002_bib2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1001\/jama.289.18.2363","article-title":"Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States","volume":"289","author":"Wolf-Maier","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2006.02.002_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1524-6175.2005.04542.x","article-title":"Ethnic differences in the treatment and control of hypertension in patients with diabetes","volume":"7","author":"Riehle","year":"2005","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib4","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2006.02.002_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.HYP.36.4.594","article-title":"Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community","volume":"36","author":"Lloyd-Jones","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1161\/01.HYP.0000035855.44620.DA","article-title":"Treatment and control of hypertension in the community: a prospective analysis","volume":"40","author":"Lloyd-James","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib8","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","article-title":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled","volume":"17","author":"Bramlage","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.283.14.1829","article-title":"Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study","volume":"283","author":"Nieto","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2006.02.002_bib10","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200005113421901","article-title":"Prospective study of the association between sleep-disordered breathing and hypertension","volume":"342","author":"Peppard","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcad.2006.02.002_bib11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","article-title":"High prevalence of unrecognized sleep apnea in drug-resistant hypertension","author":"Logan","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00004872-200018060-00004","article-title":"Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension","volume":"18","author":"Grote","year":"2000","journal-title":"J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/sleep\/24.6.721","article-title":"Sleep apnea syndrome: a possible contributing factor to resistant hypertension","volume":"24","author":"Lavie","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.pcad.2006.02.002_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.CIR.0000042706.47107.7A","article-title":"Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea","volume":"107","author":"Becker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2006.02.002_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1183\/09031936.03.00035402","article-title":"Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex","volume":"21","author":"Logan","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pcad.2006.02.002_bib16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/thx.2003.015875","article-title":"Obstructive sleep apnoea\/hypopnea syndrome and hypertension","volume":"59","author":"Robinson","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.pcad.2006.02.002_bib17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"High prevalence of primary aldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.pcad.2006.02.002_bib19","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.0000172757.96281.bf","article-title":"Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension","volume":"46","author":"Hermida","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7326\/0003-4819-135-12-200112180-00005","article-title":"Effects of diet and sodium on blood pressure: subgroup analysis of the DASH-sodium trial","author":"Vollmer","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2006.02.002_bib22","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension: comparing hemodynamic management to specialist care","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.amjhyper.2004.11.021","article-title":"Resistant hypertension revisited: a comparison of 2 university-based cohorts","volume":"18","author":"Garag","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.HYP.28.1.109","article-title":"Comparison of nifedipine alone and with diltiazem or verapamil in hypertension","volume":"28","author":"Saseen","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00005344-200006000-00017","article-title":"Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension","volume":"35","author":"Stergiou","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.pcad.2006.02.002_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.pcad.2006.02.002_bib30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pcad.2006.02.002_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2006.02.002_bib32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0091270003258189","article-title":"Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?","volume":"43","author":"Prisant","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pcad.2006.02.002_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1054\/plef.2002.0414","article-title":"An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro","volume":"67","author":"Goodfriend","year":"2002","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.pcad.2006.02.002_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","article-title":"Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea","volume":"125","author":"Calhoun","year":"2004","journal-title":"Chest"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062006000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062006000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T23:22:07Z","timestamp":1555629727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062006000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0033062006000120"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2006.02.002","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}